Hospitalization Endpoint in Clinical Trials of Outpatient Settings: using Anti-SARS-COV-2 Therapy as an Example

Alhanouf Yousef Alnafisah1 Efficacy and Safety Evaluation Department, Benefit and Risk Evaluation Directorate, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia

https://orcid.org/0009-0007-5309-7204

Ahmed Fawaz Alkhalidi1 Efficacy and Safety Evaluation Department, Benefit and Risk Evaluation Directorate, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi ArabiaCorrespondence[email protected]

Hanin Aljohani1 Efficacy and Safety Evaluation Department, Benefit and Risk Evaluation Directorate, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia

Manal Almutairi1 Efficacy and Safety Evaluation Department, Benefit and Risk Evaluation Directorate, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia

Adel Alharf2 Drug Sector, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia

Hadeel Alkofide3 Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

https://orcid.org/0000-0002-5032-1895

Hospitalization Endpoint in Clinical Trials of Outpatient Settings: using Anti-SARS-COV-2 Therapy as an Example

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Hospitalization Endpoint in Clinical Trials of Outpatient Settings: using Anti-SARS-COV-2 Therapy as an Example

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date